Biosimilar Interchangeability: A Blessing Or A Curse?
As Industry Awaits First FDA Decision, Views Are Mixed On Interchangeability
Biosimilar interchangeability is a hot topic in the US, with the first FDA decision on a formal interchangeability designation expected this month. But across the industry, views differ dramatically on the desirability and likely impact of this additional standard to biosimilarity.
You may also be interested in...
Celltrion will adopt a “next generation” innovative approach to developing biosimilars as it continues to bolster its pipeline, HoUng Kim, head of Celltrion Healthcare’s medical and marketing division, tells Generics Bulletin in an exclusive interview. But the firm sees the US interchangeability designation as an “unnecessary” regulatory barrier.
Alvotech underlined that it could “save US consumers and taxpayers billions annually,” after hitting a key landmark in its Phase III switching study for its high concentration 100mg/ml biosimilar Humira product.
Industry chiefs and experts, including Sandoz' global head of biopharmaceuticals, deliberated at the recent AAM meeting the status of biosimilars adoption in Europe and trends and opportunities to generate savings for both the US federal government and payers.